Meta-analysis of topical tazarotene in the treatment of mild to moderate acne

Cutis

Volumn 74, Issue 4 SUPPL., 2004, Pages 9-15

  Leyden, James J ^{a,b,c,d,e,f,g,h,i}  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b ALLERGAN INC   (United States)

^c Managed Care and Professional Affairs   (United States)

^d Bradley Pharmaceuticals Inc   (United States)

^e Dermik Laboratories   (United States)

^f Galderma Laboratories   (United States)

^g The Dermatology Company   (United States)

^h Ortho Dermatological ^*  (United States)

ⁱ Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAZAROTENE;

ACNE VULGARIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DATA ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ERYTHEMA; ETHNOLOGY; FEMALE; GEL; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SKIN; SKIN BURNING SENSATION; SKIN EXFOLIATION; SKIN IRRITATION;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADULT; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GELS; HUMANS; MALE; MULTICENTER STUDIES; NAPHTHALENES; NICOTINIC ACIDS; RANDOMIZED CONTROLLED TRIALS; RETINOIDS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRETINOIN; UNITED STATES;

EID: 7744231660     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979;1:1109-1110.
2. Harrison PV, Dodman B, Cunliffe WJ. Prevalence of acne [letter]. Br Med J. 1979;2:495.
3. Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol. 1998;78:451-456.
4. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol. 1998;134:454-458.
5. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(suppl 3):S200-S210.
6. Shalita AR, Webster G, Lowe N, et al. A multicenter, double-blind, randomized comparison of the efficacy and tolerability of treating facial acne vulgaris once daily with tazarotene 0.1% gel or adapalene 0.1% gel. Poster presented at: 59th Annual Meeting of the American Academy of Dermatology; March 2-7, 2001; Washington, DC. P62.
7. Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(suppl 2):4-11.
8. Shalita A, Miller B, Menter A, et al. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Poster presented at: 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. P75.
9. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(suppl 6):4-9.
10. Lowe N, Anderson N, Draelos Z, et al. Comparing the efficacy and tolerability of tazarotene 0.1% gel and tretinoin 0.025% gel in the treatment of facial acne vulgaris: a second multicenter, double-blind, randomized trial. Poster presented at: Academy 2001 Meeting of the American Academy of Dermatology; July 28-August 1, 2001; Anaheim, Calif.
11. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69(suppl 2):12-19.